LMAT Stock - LeMaitre Vascular, Inc.
Unlock GoAI Insights for LMAT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $219.86M | $193.48M | $161.65M | $154.42M | $129.37M |
| Gross Profit | $150.90M | $127.05M | $104.90M | $101.38M | $84.62M |
| Gross Margin | 68.6% | 65.7% | 64.9% | 65.7% | 65.4% |
| Operating Income | $52.26M | $36.71M | $26.83M | $36.42M | $28.79M |
| Net Income | $44.04M | $30.11M | $20.64M | $26.91M | $21.22M |
| Net Margin | 20.0% | 15.6% | 12.8% | 17.4% | 16.4% |
| EPS | $1.96 | $1.36 | $0.94 | $1.27 | $1.05 |
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2025 | Barrington Research | Upgrade | Outperform | $95 |
| February 28th 2025 | Oppenheimer | Downgrade | Perform | - |
| February 28th 2025 | Barrington Research | Downgrade | Market Perform | - |
| February 13th 2025 | Wells Fargo | Initiation | Equal Weight | $95 |
| October 15th 2024 | Cantor Fitzgerald | Initiation | Neutral | $96 |
| August 2nd 2024 | Lake Street | Resumed | Buy | $105← $85 |
| May 31st 2024 | ROTH MKM | Resumed | Buy | $100 |
| April 26th 2024 | Stifel | Upgrade | Buy | $75← $59 |
| February 6th 2024 | KeyBanc Capital Markets | Resumed | Sector Weight | - |
| October 23rd 2023 | JMP Securities | Initiation | Mkt Outperform | $60 |
| September 6th 2023 | Oppenheimer | Initiation | Outperform | $70 |
| August 3rd 2023 | Jefferies | Downgrade | Hold | $67← $63 |
| May 3rd 2023 | Barrington Research | Upgrade | Outperform | $62 |
| October 28th 2022 | Barrington Research | Downgrade | Market Perform | - |
Earnings History & Surprises
LMATEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.67 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.56 | $0.62 | +9.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.57 | $0.60 | +5.3% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.50 | $0.48 | -4.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.49 | $0.49 | 0.0% | = MET |
Q4 2024 | Oct 31, 2024 | $0.44 | $0.49 | +11.4% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.47 | $0.52 | +10.6% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.39 | $0.44 | +12.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.36 | $0.38 | +5.6% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.30 | $0.33 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.32 | $0.36 | +12.5% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $0.25 | $0.27 | +8.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $0.26 | $0.25 | -3.8% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $0.28 | $0.25 | -10.7% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $0.32 | $0.29 | -9.4% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.28 | $0.27 | -3.6% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.31 | $0.28 | -9.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.33 | $0.30 | -9.1% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $0.34 | $0.40 | +17.6% | ✓ BEAT |
Latest News
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $93
➖ NeutralLeMaitre Vascular Raises FY2025 GAAP EPS Guidance from $2.23-$2.37 to $2.48-$2.53 vs $2.27 Est; Lowers FY2025 Sales Guidance from $248.000M-$254.000M to $247.000M-$249.000M vs $250.617M Est
➖ NeutralLeMaitre Vascular Sees Q4 GAAP EPS $0.64-$0.69 vs $0.63 Est; Sees Sales $61.800M-$63.800M vs $64.324M Est
➖ NeutralLeMaitre Vascular Q3 EPS $0.75 Beats $0.57 Estimate, Sales $61.046M Miss $62.181M Estimate
📈 PositiveRoth Capital Reinstates Buy on LeMaitre Vascular, Announces $108 Price Target
📈 PositiveBarrington Research Maintains Outperform on LeMaitre Vascular, Maintains $95 Price Target
📈 PositiveBarrington Research Maintains Outperform on LeMaitre Vascular, Maintains $95 Price Target
📈 PositiveFrequently Asked Questions about LMAT
What is LMAT's current stock price?
What is the analyst price target for LMAT?
What sector is LeMaitre Vascular, Inc. in?
What is LMAT's market cap?
Does LMAT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LMAT for comparison